Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TERN

Terns Pharmaceuticals Inc

Apr 15 • 04:00PM ET

5.06

Dollar change -0.08
Percentage change -1.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO VTWO VHT IWN IWC DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	36.39%	Shs Outstand	64.58M	Perf Week	-8.17%
Market Cap	327.13M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	-1.76%	Shs Float	41.12M	Perf Month	-24.59%
Income	-90.21M	PEG	-	EPS next Q	-0.34	Inst Own	76.31%	Short Float	10.93%	Perf Quarter	-13.65%
Sales	0.00M	P/S	-	EPS this Y	-9.26%	Inst Trans	32.55%	Short Ratio	4.99	Perf Half Y	-1.94%
Book/sh	3.95	P/B	1.28	EPS next Y	-0.78%	ROA	-32.48%	Short Interest	4.49M	Perf Year	-57.05%
Cash/sh	4.07	P/C	1.24	EPS next 5Y	-	ROE	-33.89%	52W Range	3.26 - 14.04	Perf YTD	-22.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.40%	ROI	-35.33%	52W High	-63.97%	Beta	-0.56
Dividend TTM	-	Quick Ratio	22.39	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	55.21%	ATR (14)	0.51
Dividend Ex-Date	-	Current Ratio	22.39	EPS Y/Y TTM	30.50%	Oper. Margin	0.00%	RSI (14)	34.84	Volatility	6.02% 8.20%
Employees	66	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.50	Target Price	14.21
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-0.45%	Payout	-	Rel Volume	0.77	Prev Close	5.14
Sales Surprise	-	EPS Surprise	1.09%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	901.06K	Price	5.06
SMA20	-16.75%	SMA50	-24.13%	SMA200	-16.66%	Trades		Volume	695,490	Change	-1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69%
04:05PM	Loading…
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire)
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
08:05AM	Loading…
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire)
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
04:05PM	Loading…
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16%
Jun-06-23 04:30PM	Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-28-23 09:45AM	Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:05PM	Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting (GlobeNewswire)
May-24-23 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-22-23 04:05PM	Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Associations 83rd Annual Scientific Sessions (GlobeNewswire) +11.79%
May-15-23 08:05AM	Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -6.24%
May-09-23 04:05PM	Terns Pharmaceuticals to Participate in the JMP Securities 2023 Life Sciences Conference (GlobeNewswire)
May-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.61%
Apr-25-23 12:00PM	Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know (Zacks) -5.29%
Mar-30-23 02:28PM	Why Shares of Terns Pharmaceuticals Soared This Week (Motley Fool)
Mar-27-23 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates (GlobeNewswire) +5.83%
08:05AM	Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology (GlobeNewswire)
Mar-08-23 05:26AM	Investing in Terns Pharmaceuticals (NASDAQ:TERN) a year ago would have delivered you a 211% gain (Simply Wall St.)
Mar-02-23 04:05PM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-23 10:51AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
Feb-08-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice (Zacks)
Feb-02-23 04:05PM	Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference (GlobeNewswire) +5.26%
Jan-12-23 04:05PM	Terns Pharmaceuticals to Present at B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire) +8.83%
Jan-05-23 04:05PM	Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-22 04:05PM	Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -7.20%
Dec-20-22 07:40PM	Terns Announces Pricing of $75 Million Public Offering (GlobeNewswire) -5.59%
08:05AM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-19-22 04:31PM	Terns Announces Proposed Public Offering (GlobeNewswire) +30.28%
Dec-01-22 04:05PM	Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit (GlobeNewswire) -10.30%
Nov-16-22 09:31AM	We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate (Simply Wall St.)
Nov-09-22 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.10%
Nov-04-22 08:05AM	Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-26-22 04:05PM	Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-12-22 05:26AM	Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE (Zacks)
Oct-11-22 04:05PM	Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference (GlobeNewswire) +13.39%
Sep-29-22 06:03AM	The past year for Terns Pharmaceuticals (NASDAQ:TERN) investors has not been profitable (Simply Wall St.)
Sep-21-22 05:33AM	Zacks.com featured highlights include Terns Pharmaceuticals, Napco Security Technologies and AVEO (Zacks) -7.21%
Sep-07-22 04:05PM	Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-19-22 06:50AM	Terns Pharmaceuticals, Inc.'s (NASDAQ:TERN) market cap surged US$112m last week, individual investors who have a lot riding on the company were rewarded (Simply Wall St.)
Aug-12-22 08:00AM	Terns Announces $65 Million Oversubscribed Offering (GlobeNewswire) +25.31%
Aug-08-22 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-27-22 04:05PM	Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors (GlobeNewswire)
Jul-22-22 12:00PM	All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy (Zacks)
Jun-22-22 04:05PM	Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress 2022 (GlobeNewswire) +7.22%
Jun-09-22 06:31AM	We're Keeping An Eye On Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate (Simply Wall St.)
Jun-08-22 04:05PM	Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022 (GlobeNewswire)
Jun-01-22 04:05PM	Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer (GlobeNewswire)
May-16-22 04:05PM	Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Apr-05-22 01:38PM	Investors in Terns Pharmaceuticals (NASDAQ:TERN) have unfortunately lost 86% over the last year (Simply Wall St.)
Apr-04-22 04:05PM	Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-22 04:05PM	Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201 (GlobeNewswire)
Mar-03-22 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-28-22 04:05PM	Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire)
Feb-04-22 11:37AM	Terns Pharmaceuticals, Inc. (NASDAQ:TERN): Are Analysts Optimistic? (Simply Wall St.) -5.13%
Feb-02-22 05:38PM	Matthews International Capital Management Llc Buys Atlassian Corporation PLC, Pinduoduo Inc, ... (GuruFocus.com) -12.59%
Jan-06-22 07:05AM	Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer (GlobeNewswire)
Jan-03-22 04:05PM	Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference (GlobeNewswire) -5.23%
Nov-15-21 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-12-21 07:05AM	Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021 (GlobeNewswire)
Nov-10-21 07:17AM	Terns' Potential NASH Candidate Shows Potent Liver Target Engagement (Benzinga)
Nov-09-21 04:05PM	Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR- agonist TERN-501 (GlobeNewswire) -5.49%
Nov-03-21 02:52PM	Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Oct-18-21 04:05PM	Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021 (GlobeNewswire)
Oct-05-21 04:05PM	Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference (GlobeNewswire)
Oct-04-21 08:38AM	Should I Avoid Terns Pharmaceuticals, Inc. (TERN)? (Insider Monkey)
Sep-28-21 04:05PM	Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors (GlobeNewswire)
Sep-15-21 06:07PM	Goldman Sachs Sees These 2 Stocks Surging Over 70% (TipRanks)
Sep-08-21 07:05AM	Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 (GlobeNewswire) -6.67%
Sep-02-21 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-21 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) -11.01%
Aug-03-21 04:05PM	Terns Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Jun-24-21 04:05PM	Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201 (GlobeNewswire) -9.22%
Jun-14-21 12:41PM	Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist (Benzinga) -12.46%

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vivo Opportunity, LLC	10% Owner	Apr 03 '24	Sale	6.20	138,066	856,009	268,573	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 02 '24	Sale	6.65	101,480	674,842	272,722	Apr 03 08:47 PM
Vivo Opportunity, LLC	10% Owner	Apr 01 '24	Sale	6.99	181,117	1,266,008	275,772	Apr 03 08:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience